Hematology. American Society of Hematology. Education Program
| 短名 | Hematology. Am. Soc. Hematol. Educ. Program. |
| Journal Impact | 3.09 |
| 国际分区 | HEMATOLOGY(Q2) |
| 期刊索引 | SCI Q2中科院 3 区 |
| ISSN | 1520-4383, 1520-4391 |
| h-index | 104 |
| 国内分区 | 教育学(3区)教育学学科教育(3区)教育学血液学(3区) |
HEMATOLOGY 是 ASH 教育计划，由美国血液学会 (ASH) 每年出版一卷。
期刊主页| 涉及主题 | 医学生物内科学免疫学遗传学病理外科化学生物化学心理学疾病重症监护医学精神科肿瘤科细胞生物学癌症研究生物信息学基因干细胞抗体 |
| 出版信息 | 出版商: American Society of Hematology，出版周期: ，期刊类型: journal |
| 基本数据 | 创刊年份: 2001，原创研究文献占比: 92.47%，自引率:0.00%， Gold OA占比: 0.53% |
期刊引文格式
这些示例是对学术期刊文章的引用，以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章，因此这些字段是可选的。有些电子期刊不提供页面范围，而是列出文章标识符。在这种情况下，使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用，以及它们应该如何出现在您的参考文献中。
专利引用格式
最新文章
Bispecific antibody therapies
2023-12-8
Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL
2023-12-8
Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas
2023-12-8
Management of pregnant women who have bleeding disorders
2023-12-8
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease
2023-12-8
Clinical research in the community
2023-12-8
Managing side effects: guidance for use of immunotherapies in multiple myeloma
2023-12-8
How to diagnose and manage antiphospholipid syndrome
2023-12-8
MRD-directed therapy in CLL: ready for prime time?
2023-12-8
Provoked vs minimally provoked vs unprovoked VTE: does it matter?
2023-12-8
Dual-targeted regimens for the frontline treatment of CLL
2023-12-8
Hodgkin lymphoma treatment for older persons in the modern era
2023-12-8
Management of limited-stage Hodgkin lymphoma
2023-12-8
Pyruvate kinase activators for treatment of pyruvate kinase deficiency
2023-12-8
Are transplant indications changing for myelofibrosis?
2023-12-8
The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation
2023-12-8
Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line
2023-12-8
Thrombotic anti-PF4 immune disorders: HIT, VITT, and beyond
2023-12-8
Labor and delivery: DIC, HELLP, preeclampsia
2023-12-8
Stem cell transplantation for ALL: you've always got a donor, why not always use it?
2023-12-8
Understanding differential technologies for detection of MRD and how to incorporate into clinical practice
2023-12-8
Alloimmunization and hyperhemolysis in sickle cell disease
2023-12-8
How to avoid early mortality in acute promyelocytic leukemia
2023-12-8
Multiple myeloma: a paradigm for blending community and academic care
2023-12-8
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?
2023-12-8
The approach of HMA plus VEN with or without BMT for all patients with AML
2023-12-8
Approaches to optimize outcomes in transplant recipients
2023-12-8
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies
2023-12-8
Should posttransplant cyclophosphamide be considered standard of care for pediatric transplantation of acute leukemia?
2023-12-8
Improving long-term outcomes with intensive induction chemotherapy for patients with AML
2023-12-8
Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia
2023-12-8
The optimal management of relapsed and refractory Hodgkin lymphoma: post–brentuximab and checkpoint inhibitor failure
2023-12-8
Richter transformation—is there light at the end of this tunnel?
2023-12-8
Managing pregnancy in patients with sickle cell disease from a transfusion perspective
2023-12-8
CAR T-cell therapy in aggressive lymphomas—identifying prognostic and predictive markers
2023-12-8
Clonal hematopoiesis in frequent whole blood donors
2023-12-8
Medical consult: aHUS, TTP? How to distinguish and what to do
2023-12-8
The dos, don'ts, and nuances of thrombophilia testing
2023-12-8
Using disease-modifying therapies in sickle cell disease
2023-12-8
Leveraging health care technology to improve health outcomes and reduce outcome disparities in AYA leukemia
2023-12-8
Accelerated-phase CML: de novo and transformed
2023-12-8
Novel therapies upon failure of HMA plus venetoclax
2023-12-8
How to manage ITP with life-threatening bleeding
2023-12-8
Preventing relapse after CD19 CAR T-cell therapy for pediatric ALL: the role of transplant and enhanced CAR T cells
2023-12-8
Cytoreduction for ET and PV: who, what, when, and how?
2023-12-8
MSM and blood donation: shifting to individualized risk assessment
2023-12-8
Sex, lies, and iron deficiency: a call to change ferritin reference ranges
2023-12-8
The role of emicizumab in acquired hemophilia A
2023-12-8
Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes?
2023-12-8
How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome
2023-12-8
帮你贴心管理全部的文献
研飞ivySCI，高效的论文管理
投稿经验分享
分享我的经验，帮你走得更远